2014
DOI: 10.1016/j.ejphar.2013.12.018
|View full text |Cite
|
Sign up to set email alerts
|

Cardiac SERCA2A/B: Therapeutic targets for heart failure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
32
0
7

Year Published

2015
2015
2023
2023

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 68 publications
(41 citation statements)
references
References 99 publications
2
32
0
7
Order By: Relevance
“…In contrast to the strong effect of LRP1 deficiency on SERCA2, LRP1 deficiency does not prevent the downregulatory effect of hypoxia on NCX-1 and CAV1.2. These results support a pivotal role of SERCA2 on the maintenance of calcium metabolism and are in agreement with the enormous potential of SERCA2 restoration by pharmacological action or gene delivery in the treatment of heart failure [37][38][39].…”
Section: Impact Of Lrp1 Deficiency On Calcium-handling Proteins and Csupporting
confidence: 87%
“…In contrast to the strong effect of LRP1 deficiency on SERCA2, LRP1 deficiency does not prevent the downregulatory effect of hypoxia on NCX-1 and CAV1.2. These results support a pivotal role of SERCA2 on the maintenance of calcium metabolism and are in agreement with the enormous potential of SERCA2 restoration by pharmacological action or gene delivery in the treatment of heart failure [37][38][39].…”
Section: Impact Of Lrp1 Deficiency On Calcium-handling Proteins and Csupporting
confidence: 87%
“…By sequestering cytosolic calcium in the endoplasmic reticulum, SERCA further regulates important signaling mechanisms critical for normal cell function, growth, and survival. Under conditions of heart failure, decreased Ca 21 uptake due to loss of SERCA activity is observed in humans, as well as in animal models of heart failure (35). Irreversible oxidation of SERCA and subsequent loss of activity occurs in the presence of higher levels of reactive oxygen species (36).…”
Section: Discussionmentioning
confidence: 99%
“…Age, pulmonary artery wedge pressure, LVEDVI, study. 12,13 SERCA2α, in particular, has received considerable attention as a therapeutic target for heart failure, 24 because SERCA2α gene therapy appears to improve ventricular contractility and reduce the incidence of lethal arrhythmias in animal models. 25, 26 Furthermore, several clinical trials are investigating the potential benefit of SERCA2α gene therapy for systolic heart failure.…”
Section: Comparison Of the Cvf In The Bif And Mof Groupsmentioning
confidence: 99%